Viibryd Tablet
Product Images NDC 0456-1110

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Viibryd (NDC 0456-1110). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Structural Formula For Vilazodone HCl Is 2-benzofurancarboxamide, 5-[4-[4-(5-cyano-1h-indol-3-yl)butyl]-1-piperazinyl]-, Hydrochloride (1:1). Its Molecular Weight Is 477.99. (Viibryd 01)

FDA Label Image

Figure 1. Effect Of Other Drugs On Vilazodone Pharmacokinetics (Viibryd 02)

This text seems to be presenting data related to changes in drug concentrations due to K Fold Change and 90% C1, with respect to different inhibitors. It mentions specific drugs and their maximum concentrations (Cmax) and average concentrations following the use of certain inhibitors. The text also makes reference to a graph or chart showing the changes, possibly over time.*

FDA Label Image

Figure 2. Impact Of Vilazodone On Other Drug Pharmacokinetics (Viibryd 03)

FDA Label Image

Figure 3: Impact Of Intrinsic Factors On Vilazodone Pharmacokinetics (Viibryd 04)

This is not-available. The text seems to be a combination of numerical values and random sentences that do not make any sense. It is not possible to generate a useful description using this text.*

FDA Label Image

Viibryd 05

FDA Label Image

Allergan Logo (Viibryd 06)

FDA Label Image

Ndc 0456-1110-30viibrydvilazodone Hcitablets30 Tablets10 mgrx Only (Viibryd 07)

Viibryd® is a medication containing 10 mg of vilazodone hydrochloride in tablet form. The usual recommended dosage is provided in the package insert, and the medication should be kept in a tightly closed container out of reach of children. Viibryd® is distributed by Allergan USA, Inc. and is a registered trademark. The medication is only available with a prescription and should be accompanied by a medication guide for each patient. The text also includes information on storage temperature ranges and the manufacturer's address.*

FDA Label Image

Ndc 0456-1120-30viibrydvilazodone Hcitablets30 Tablets20 mgrx Only (Viibryd 08)

Viibryd is a medication used to treat major depression. Each bottle contains 30 tablets of 20 mg each. Dispense the accompanying medication guide to each patient. Viibryd is a registered trademark of Forest Laboratories LLC. The medicine is distributed by Allergan, a company located in Irvine, CA.*

FDA Label Image

Ndc 0456-1140-30viibrydvilazodone Hcitablets30 Tablets40 mgrx Only (Viibryd 09)

This is a prescription medication called Viibryd. Each package contains 30 tablets that have 40 mg of vilazodone HCI. It is recommended to provide the medication guide to each patient who receives it.*

FDA Label Image

Principal Display Panelndc 0456-1100-31viibrydvilazodone Hci Tablets10 mgdays 1-720 mgdays 8-1440 mgdays 15-30rx Only (Viibryd 0a)

FDA Label Image

Principal Display Panelndc 0456-1101-30viibrydvilazodone Hci Tablets10 mgdays 1-720 mgdays 8-30rx Only (Viibryd 0b)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.